Figure 2.

Affected pathways in laminopathies and potential avenues for therapeutic intervention. Alterations in multiple pathways contribute to the pathogenesis of laminopathies. Strategies tested in preclinical or clinical studies are indicated with solid arrows. Strategies to alter Wnt signaling to β-catenin or growth hormone signaling via Jak and Stat proteins, which are altered in mouse models of laminopathies but have not been tested in animal models or clinical trials, are indicated with dashed arrows. Agents developed to reduce or block activity of progerin, FTIs^{132,133,165,166}, antisense oligonucleotides¹³⁶, and small molecules that inhibit progerin interaction with LMNA¹⁶⁹ have been tested.